MabVax Therapeutics Inc. Company Profile

17:37 EDT 20th March 2018 | BioPortfolio

MabVax was formed to commercialize the work of Dr. Phil Livingston and colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC) who over the last 25 years have developed monovalent cancer vaccines against ten distinct antigenic targets on various types of cancer cells. These vaccines target gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. Vaccines, or passively administered antibodies developed from these vaccines, produced evidence demonstrating the prevention of tumor recurrence and prolonged survival in preclinical models and supporting data in early Phase I human clinical trials. The company is initially focused on developing polyvalent vaccines and a pipeline of fully human monoclonal antibodies to address a variety of cancers including sarcoma, small cell lung cancer, and melanoma. MabVax closed a Series A venture financing with GBP Capital in late February 2008.

News Articles [743 Associated News Articles listed on BioPortfolio]

Active-Investors: Wired News - MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873

LONDON, UK / ACCESSWIRE / December 22, 2017 / has just released a free research report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax"). If you want access to th...

MabVax completes enrollment & initial patient dosing in expanded cohort of phase 1 trial evaluating MVT─5873 in combo with first─line chemotherapy

MabVax Therapeutics Holdings, a clinical─stage biotechnology company focused on the development of antibody─based products to address unmet medical needs in the treatment of cancer, announced the ...

MabVax starts dosing patients in Phase l trial of MVT-1075

MabVax Therapeutics has started dosing patients in the initial round of a Phase l clinical trial evaluating MVT-1075 for the...Read More... The post MabVax starts dosing patients in Phase l trial of M...

MabVax CEO Looks for Potential Deals at JPM to Support its Human Antibody Programs

MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial.

MabVax Therapeutics (MBVX) Presents At BIO CEO & Investor Conference - Slideshow

INVESTOR NOTICE: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX

LOS ANGELES, CA / ACCESSWIRE / February 8, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MabVax Ther...

MabVax reports Phase I data for cancer candidate MVT-1075

MabVax Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 28112017] Prices from USD $250

SummaryMabVax Therapeutics Inc MabVax Therapeutics, a subsidiary of MabVax Therapeutics Holdings Inc is a biopharmaceutical company that develops and commercializes anticancer immunotherapies from ant...

PubMed Articles [401 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 1 of JOPT Special Issue.

Introduction to Volume 2 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [134 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1200 Associated Companies listed on BioPortfolio]

MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer....

MabVax Therapeutics Inc.

MabVax was formed to commercialize the work of Dr. Phil Livingston and colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC) who over the last 25 years have developed monovalent cancer vacc...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "MabVax Therapeutics Inc." on BioPortfolio

We have published hundreds of MabVax Therapeutics Inc. news stories on BioPortfolio along with dozens of MabVax Therapeutics Inc. Clinical Trials and PubMed Articles about MabVax Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MabVax Therapeutics Inc. Companies in our database. You can also find out about relevant MabVax Therapeutics Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Corporate Database Quicklinks

Searches Linking to this Company Record